Carolyn Millar is a Senior Lecturer in the department of haematology and a Consultant Haematologist specialising in haemostasis and thrombosis. She is the clinical lead in haemophilia at the Hammersmith hospital. Dr Millar completed undergraduate medical training at the University of Newcastle-upon-Tyne, graduating with honours. She undertook postgraduate medical training at University College London, the National Hospital for Neurology & Neurosurgery, Queen Square, and St George’s Hospital, Tooting. Dr Millar’s haematology training was largely undertaken at the Hammersmith, Great Ormond Street and Royal Free hospitals, where her doctoral thesis investigated the role of glycans in von Willebrand factor clearance and their relation to von Willebrand disease. Dr Millar has continued to study the configuration, function and kinetics of von Willebrand factor since being awarded a HEFCE clinical senior lectureship to start her position at Imperial College in December 2008 . As well as von Willebrand disease, her clinical interests include obstetric haemostasis, rare bleeding disorders, haemophilia and anticoagulant therapy. Dr Millar has led on the UK surveillance of vCJD in patients with bleeding disorders since 2002.
Dr Millar supervises postdoctoral research fellows and MSc., BSc., MD and PhD students. Since 2012 she has been course co-director of the intercalated BSc programme in haematology and has been head of a year 3 clinical firm since 2009. Dr Millar also lectures on year 1, 2, 4 and 5 and graduate entry courses and on the Biomedical science programme. She is personal tutor to students in years 1,3,4, 5 and 6. Dr Millar obtained a diploma in undergraduate teaching in 2012 and in 2013 was awarded an Imperial College Teaching Excellence award
et al., 2017, Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A, British Journal of Haematology, Vol:176, ISSN:0007-1048, Pages:796-804
Millar CM, Laffan MA, 2017, Drug therapy in anticoagulation: which drug for which patient?, Clinical Medicine, Vol:17, ISSN:1470-2118, Pages:233-244
Millar CM, Laffan MA, 2017, Corrigendum: Drug therapy in anticoagulation: which drug for which patient?, Clin Med (lond), Vol:17, Pages:347-349
Millar CM, Laffan MA, 2017, Drug therapy in anticoagulation: which drug for which patient? (vol 17, pg 233, 2016), Clinical Medicine, Vol:17, ISSN:1470-2118, Pages:347-349
et al., 2017, Von Willebrand Factor modulates blood vessel formation and function via Angiopoietin-2, 2nd Joint Meeting of the European-Society-for-Microcirculation (ESM) and European-Vascular-Biology-Organisation (EVBO), KARGER, Pages:38-38, ISSN:1018-1172